We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-0.27%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
+$1.73M
Cap. Flow
-$160M
Cap. Flow %
-10.45%
Top 10 Hldgs %
69.53%
Holding
250
New
32
Increased
47
Reduced
70
Closed
82

Top Buys

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$13.5M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$11.9M
3
ESPR
Esperion Therapeutics
ESPR
+$4.02M
4
AIXC
AIxCrypto Holdings Inc
AIXC
+$2.59M
5
HURA
TuHURA Biosciences
HURA
+$2.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$59.2M
2
UTHR icon
United Therapeutics
UTHR
+$6.78M
3
TSRO
TESARO, Inc.
TSRO
+$5.95M
4
KITE
Kite Pharma, Inc.
KITE
+$4.37M
5
SPNC
Spectranetics Corp
SPNC
+$3.48M

Sector Composition

Rank Sector Weight
1 Healthcare 7.34%
2 Technology 0.16%
3 Materials 0.11%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
51
CALL
PTC Therapeutics
PTCT
$6.25B
$2.56M 0.17%
1,277
+300
+31% +$5.87K
SRPT icon
52
PUT
Sarepta Therapeutics
SRPT
$1.63B
$2.35M 0.15%
518
+452
+685% +$18.1K
SGEN
53
DELISTED
Seagen Inc. Common Stock
SGEN
$2.32M 0.15%
42,646
-42,516
-50% -$2.18M
INCY icon
54
PUT
Incyte
INCY
$26B
$2.15M 0.14%
184
+84
+84% +$10.6K
MBAI
55
Check-Cap
MBAI
$8.12M
$2.12M 0.14%
4,937
-975
-16% -$423K
IMMU
56
CALL
DELISTED
Immunomedics Inc
IMMU
$1.85M 0.12%
1,322
-175
-12% -$1.74K
HURA
57
TuHURA Biosciences
HURA
$136M
$1.78M 0.12%
121
+84
+227% +$2.3M
KDMN
58
DELISTED
Kadmon Holdings, Inc.
KDMN
$1.76M 0.12%
525,695
-17,174
-3% -$49.1K
ARAV
59
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.73M 0.11%
+117,883
New +$11.9M
WVE icon
60
Wave Life Sciences
WVE
$1.13B
$1.63M 0.11%
75,000
-66,700
-47% -$1.34M
AIXC
61
AIxCrypto Holdings Inc
AIXC
$16.7M
$1.63M 0.11%
+37
New +$2.59M
BIOA
62
DELISTED
BioAmber Inc.
BIOA
$1.56M 0.1%
3,180,973
+1,754,056
+123% +$2.09M
AMAG
63
DELISTED
AMAG Pharmaceuticals
AMAG
$1.48M 0.1%
80,108
-8,770
-10% -$163K
MBOT icon
64
Microbot Medical
MBOT
$113M
$1.46M 0.1%
83,427
-2,263
-3% -$39.9K
TRAW icon
65
Traws Pharma
TRAW
$7.81M
$1.44M 0.09%
150
+11
+8% +$114K
ATNM icon
66
Actinium Pharmaceuticals
ATNM
$27.2M
$1.4M 0.09%
+81,137
New +$1.78M
TSRO
67
PUT
DELISTED
TESARO, Inc.
TSRO
$1.34M 0.09%
104
-814
-89% -$101K
MNKD icon
68
PUT
MannKind Corp
MNKD
$1.21B
$1.31M 0.09%
6,048
-78
-1% -$122
TSRO
69
CALL
DELISTED
TESARO, Inc.
TSRO
$1.29M 0.08%
100
– –
CRDF icon
70
Cardiff Oncology
CRDF
$63.6M
$1.23M 0.08%
+23,469
New +$1.46M
SCPX
71
DELISTED
Scorpius Holdings, Inc.
SCPX
$1.12M 0.07%
6
-1
-14% -$154K
LUMO
72
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.02M 0.07%
+111
New +$8.51K
EIGR
73
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.02M 0.07%
3,083
-4,354
-59% -$1.19M
CVM icon
74
CEL-SCI Corp
CVM
$21M
$976K 0.06%
+19,594
New +$1.24M
ONCS
75
DELISTED
OncoSec Medical Incorporated
ONCS
$968K 0.06%
4,592
+192
+4% +$42.8K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sabby Management held 250 positions worth $1.53B, up 0.11% from $1.53B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management withdrew a net $160M in Q3 2017, closing 82 positions and reducing 70 holdings. Its most notable exit was United Therapeutics, an estimated $6.78M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 7.3% of assets, down from 13% a quarter earlier, followed by Technology and Materials.

Against the trend, Sabby Management opened a new position in Sio Gene Therapies Inc. Common Stock worth $4.42M.

  • Sabby Management's largest Q3 2017 buy was Sio Gene Therapies Inc. Common Stock: 80,320 shares worth $4.42M.
  • Sabby Management added most to TuHURA Biosciences in Q3 2017, an estimated $2.3M increase.
  • Sabby Management's biggest Q3 2017 reduction was Bristol-Myers Squibb, cutting an estimated $59.2M.
  • Sabby Management fully exited United Therapeutics in Q3 2017, selling an estimated $6.78M.
  • Sabby Management's ten largest holdings make up 70% of its $1.53B portfolio in Q3 2017.
  • Sabby Management opened 32 new positions and closed 82 in Q3 2017.
  • Sabby Management's portfolio value rose 0.11% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.